# Amantadine

## Dopadine100mg

| TAH Drug Code      | [ODOP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ODOP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Parkinsonism of various origin, senile Parkinsonism, residual symptoms & discomfort after stereotactic operations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Parkinson's disease: Adult: Monotherapy, 100 mg orally twice daily; may titrate up to 400 mg/day in divided doses. During a serious related disease or receiving high-dose anti-Parkinson's disease treatment, the initial dose of this agent is 100 mg once a day, After 1-7 weeks, if necessary, may titrate up to 100 mg twice a day; and additionally up to 400 mg/day in divided doses. Initiating levodopa and amantadine concurrently, hold amantadine at 100 mg once or twice daily while gradually increasing levodopa. Prophylaxis or treatment of Influenza A symptoms: (Due to high resistance rates, amantadine is no longer recommended by the CDC for the treatment or prophylaxis of influenza A.) Adult: 100-200mg/day. Children > 10 years old or > 45 kg: 100mg BID. Children > 5 years old: 100mg QD. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Severe CHF (NYHA class IV), cardiomyopathies & myocarditis, 2nd or 3rd degree AV block, existing bradycardia under 55 beats/min, known prolonged QT interval (Bazett QTc > 420 ms) or discernible U-waves or congenital QT syndrome in the family anamnesis , history of serious ventricular arrhythmias including torsade de pointes, simultaneous treatment with budipine or other drugs that prolong the QT interval, reduced levels of potassium or magnesium in the blood. Pregnancy & lactation.                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Orthostatic hypotension (1-5% ; 13% (extended-release)), Peripheral edema (1-5% ; 16% (extended-release)), Constipation (1-5% ; 13% (extended-release)), Loss of appetite (1-6%), Nausea (5-10%), Xerostomia (1-5% ; 16% (extended-release)), Abnormal gait (3%), Dizziness (5-10% ; 16% (extended-release)), Insomnia (5-10%), Agitation (1-5%), Anxiety (1-7%), Depression (1-6% .), Dream disorder (1-5%), Feeling nervous (1-5%), Hallucinations (1-5% .; 21% (extended-release)), Urinary tract infectious disease (10%), Falls (13%) Serious: Congestive heart failure (0.1-1%), Leukopenia (<0.1%), Neutropenia (<0.1%), Neuroleptic malignant syndrome, Suicidal intent (<0.1% ; 2% (extended-release))                                                                                                   |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

